Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
Abstract© 2017 Macmillan Publishers Limited, part of Springer Nature. Multiple myeloma (MM), an incurable plasma cell malignancy, requires localisation within the bone marrow. This microenvironment facilitates crucial interactions between the cancer cells and stromal cell types that permit the tumour to survive and proliferate. There is increasing evidence that the bone marrow mesenchymal stem cell (BMMSC) is stably altered in patients with MM - a phenotype also postulated to exist in patients with monoclonal gammopathy of undetermined significance (MGUS) a benign condition that precedes MM. In this study, we describe a mechanism by which increased expression of peptidyl arginine deiminase 2 (PADI2) by BMMSCs in patients with MGUS and MM directly alters malignant plasma cell phenotype. We identify PADI2 as one of the most highly upregulated transcripts in BMMSCs from both MGUS and MM patients, and that through its enzymatic deimination of histone H3 arginine 26, PADI2 activity directly induces the upregulation of interleukin-6 expression. This leads to the acquisition of resistance to the chemotherapeutic agent, bortezomib, by malignant plasma cells. We therefore describe a novel mechanism by which BMMSC dysfunction in patients with MGUS and MM directly leads to pro-malignancy signalling through the citrullination of histone H3R26.
CitationMcNee, G., Eales, K. L., Wei, W., Williams, D. S. et al. (2017) Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma, Leukemia, 31, pp. 373–381. DOI: 10.1038/leu.2016.187
PublisherSpringer Science and Business Media LLC
PubMed ID27400413 (pubmed)
Description© 2016The Authors. Published by Springer Nature. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1038/leu.2016.187
SponsorsGMcN and DSW were supported by Bloodwise grant number 13039, SE and DBB by Cancer Research UK grant C1520/A9992 and KLE through Doctoral Training Grant from the Medical Research Council, reference MR/K501323/1.
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
- Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.
- Authors: McNee G, Eales KL, Wei W, Williams DS, Barkhuizen A, Bartlett DB, Essex S, Anandram S, Filer A, Moss PA, Pratt G, Basu S, Davies CC, Tennant DA
- Issue date: 2017 Feb
- Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
- Authors: Frassanito MA, Desantis V, Di Marzo L, Craparotta I, Beltrame L, Marchini S, Annese T, Visino F, Arciuli M, Saltarella I, Lamanuzzi A, Solimando AG, Nico B, De Angelis M, Racanelli V, Mariggiò MA, Chiacchio R, Pizzuti M, Gallone A, Fumarulo R, D'Incalci M, Vacca A
- Issue date: 2019 Feb
- Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
- Authors: Andersen NF, Kristensen IB, Preiss BS, Christensen JH, Abildgaard N
- Issue date: 2015 Sep
- Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
- Authors: Sati HI, Apperley JF, Greaves M, Lawry J, Gooding R, Russell RG, Croucher PI
- Issue date: 1998 May